Sandy Mahatme

Sandesh Mahatme currently works at Epirium Bio, Inc., as Director from 2020, Idorsia Ltd., as Non-Executive Director from 2020, Idorsia Pharmaceuticals Ltd., as Director from 2020, CRISPR Therapeutics AG, as Independent Director from 2024, New York State Bar Association, as Member, and Vor Biopharma, Inc., as Chief Financial & Business Officer from 2025.
Mr. Mahatme also formerly worked at Elcelyx Therapeutics, Inc., as Independent Director, Spyre Therapeutics, Inc., as Independent Director from 2015 to 2022, Flexion Therapeutics, Inc., as Independent Director from 2014 to 2021, Celgene Corp., as Senior VP-Finance & Corporate Development from 2006 to 2012, Sarepta Therapeutics, Inc., as Chief Financial & Business Officer, Executive VP from 2017 to 2020, Celgene Switzerland SARL, as Senior Vice President, and National Resilience, Inc., as President, Chief Financial & Operating Officer from 2020 to 2024.
Mr. Mahatme received his graduate degree from Cornell Law School and graduate degree from New York University School of Law.